Uterine carcinosarcoma
Jump to navigation
Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Uterine carcinosarcoma | |
---|---|
Diagnosis in short | |
Carcinosarcoma. H&E stain. | |
| |
LM | biphasic tumour: (1) malignant epithelial component (carcinoma), (2) mesenchymal differentiation ("sarcoma") |
LM DDx | undifferentiated endometrial sarcoma, adenosarcoma of the uterus, endometrial carcinomas |
Site | uterus - see uterine tumours |
| |
Clinical history | +/-previous radiation exposure |
Prevalence | uncommon |
Prognosis | poor |
Uterine carcinosarcoma, also known as malignant mixed muellerian tumour (abbreviated MMMT), is an uncommon malignant uterine tumour.
General
- Generally considered metaplastic carcinomas (putatively arise from epithelial cells only); they are not true sarcomas.[1][2]
- Probably represent poorly differentiated endometrial carcinoma with metaplastic changes.[3]
- Typically metstasize as carcinoma.[4]
- Associated with previous radiation exposure.
- Aggressive/poor prognosis;[5] in one series 5 year survival ~= 30-35%.[6]
- Case reports of MMMT in ovary and fallopian tube.
Microscopic
Features:[7]
- Biphasic tumour:
- Malignant glandular component (adenocarcinoma).
- Malignant stromal component (one of the following):
- Homologous type (tissue native to uterus):
- Smooth muscle (leiomyosarcoma).
- Fibrous tissue (fibrosarcoma).
- Heterologous type (tissue not native to the uterus):
- Skeletal muscle (rhabdomyosarcoma).
- Cartilage (chondrosarcoma).
- Bone (osteosarcoma).
- Undifferentiated sarcoma (pleomorphic undifferentiated sarcoma).
- Homologous type (tissue native to uterus):
DDx:
Images
www:
IHC
Features:
- CD10 +ve/-ve (16 +ve of 27[8]).
- SMA -ve/+ve (11 +ve of 27[8]).
- Desmin -ve/+ve (9 +ve of 27[8]).
- p53 -ve (8 +ve of 27[8]).
See also
References
- ↑ Cantrell, LA.; Blank, SV.; Duska, LR. (Jun 2015). "Uterine carcinosarcoma: A review of the literature.". Gynecol Oncol 137 (3): 581-588. doi:10.1016/j.ygyno.2015.03.041. PMID 25805398.
- ↑ Artioli, G.; Wabersich, J.; Ludwig, K.; Gardiman, MP.; Borgato, L.; Garbin, F. (Apr 2015). "Rare uterine cancer: carcinosarcomas. Review from histology to treatment.". Crit Rev Oncol Hematol 94 (1): 98-104. doi:10.1016/j.critrevonc.2014.10.013. PMID 25468677.
- ↑ D'Angelo, E.; Prat, J. (Jan 2010). "Uterine sarcomas: a review.". Gynecol Oncol 116 (1): 131-9. doi:10.1016/j.ygyno.2009.09.023. PMID 19853898.
- ↑ Lopez-Garcia, MA.; Palacios, J. (Nov 2010). "Pathologic and molecular features of uterine carcinosarcomas.". Semin Diagn Pathol 27 (4): 274-86. PMID 21309261.
- ↑ Ivy, JJ.; Unger, JB.. "Malignant mixed mullerian sarcomas of the uterus--the LSUHSC Shreveport experience.". J La State Med Soc 156 (6): 324-6. PMID 15688674.
- ↑ Callister, M.; Ramondetta, LM.; Jhingran, A.; Burke, TW.; Eifel, PJ. (Mar 2004). "Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.". Int J Radiat Oncol Biol Phys 58 (3): 786-96. doi:10.1016/S0360-3016(03)01561-X. PMID 14967435.
- ↑ Humphrey, Peter A; Dehner, Louis P; Pfeifer, John D (2008). The Washington Manual of Surgical Pathology (1st ed.). Lippincott Williams & Wilkins. pp. 428. ISBN 978-0781765275.
- ↑ 8.0 8.1 8.2 8.3 Koivisto-Korander, R.; Butzow, R.; Koivisto, AM.; Leminen, A. (Jun 2011). "Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.". Tumour Biol 32 (3): 451-9. doi:10.1007/s13277-010-0138-1. PMID 21161468.